The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Development of a FKSI-23: A new bespoke health-related quality of life (HRQOL) questionnaire for the advanced and adjuvant setting in renal cell carcinoma (RCC).
 
Cristiane Bergerot
No Relationships to Disclose
 
Paulo Bergerot
No Relationships to Disclose
 
Daniela Castro
No Relationships to Disclose
 
Benjamin Mercier
No Relationships to Disclose
 
Elizabeth Nally
No Relationships to Disclose
 
Adil Ali
No Relationships to Disclose
 
Thomas Hutson
Employment - Texas Oncology
Honoraria - Astellas Pharma; Bayer/Onyx; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bayer/Onyx; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Novartis; Pfizer
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Johnson & Johnson (Inst); Pfizer (Inst)
 
Axel Bex
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
Speakers' Bureau - Ipsen
Research Funding - Pfizer (Inst)
 
Sarah Psutka
Leadership - Janssen
Honoraria - AstraZeneca
Consulting or Advisory Role - CG Oncology; ImmunityBio; Janssen; Merck
Research Funding - Janssen; Steba Biotech
Travel, Accommodations, Expenses - medtronic
 
Brian Rini
Leadership - MashupMD
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; HiberCell; Merck; Pfizer
Research Funding - ADC Therapeutics (Inst); Adela (Inst); Aravive (Inst); Arcus Biosciences (Inst); Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Gilead Sciences (Inst); HiberCell (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - Eisai
 
Elizabeth Plimack
Consulting or Advisory Role - 23andMe; Abbvie; Adaptimmune; Astellas Pharma; AstraZeneca; Aura Biosciences; Bristol-Myers Squibb/Medarex; Eisai; EMD Serono; Merck; Pfizer; Seagen; Signatera; Synthekine
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
 
Viraj Master
Honoraria - Ethicon; Exelixis
Research Funding - Exelixis; Merck (Inst)
 
Viktor Grünwald
Employment - University Hospital Essen
Stock and Other Ownership Interests - AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Genmab; MSD
Honoraria - Advanced Accelerator Applications/Novartis; Amgen; Apogepha; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Ipsen; Janssen-Cilag; Merck Serono; MSD Oncology; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Cureteq; Debiopharm Group; Eisai; Gilead Sciences; Ipsen; Janssen-Cilag; MSD Oncology; Novartis; Oncorena; PCI Biotech; Pfizer; Synthekine
Research Funding - Amgen (Inst); Bicycle Therapeutics (Inst); BMS (Inst); Gilead Sciences (Inst); Ipsen (Inst); MSD Oncology (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; Janssen; Merck Serono; Pfizer
 
Laurence Albiges
Consulting or Advisory Role - Astellas Pharma (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo Europe GmbH (Inst); Eisai (Inst); Ipsen (Inst); Janssen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Telix Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - BMS; Ipsen; MSD; Pfizer
 
Toni Choueiri
Stock and Other Ownership Interests - Abalytics Oncology; Bicycle Therapeutics; Curesponse; Inndura; Osel; Pionyr; Precede Bio; Primium; Tempest Therapeutics
Honoraria - Alkermes; Analysis Group; Aravive; Arcus Biosciences; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Clinical Care Options; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; HiberCell; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - alkermes; Analysis Group; Aravive; Arcus Biosciences; Arcus Biosciences; ASCO; AstraZeneca; Bayer; bicycle; Bicycle Therapeutics; Bristol-Myers Squibb; Clinical Care Options; Curesponse; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Neomorph; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NiKang Therapeutics (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy (Inst); ctDNA technologies; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Other Relationship - Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel
 
Sumanta Pal
Speakers' Bureau - IntrinsiQ; MJH Life Sciences; Peerview
Travel, Accommodations, Expenses - crispr therapeutics; Exelixis; Ipsen
 
David Cella
Stock and Other Ownership Interests - FACIT.org
Consulting or Advisory Role - Abbvie; Astellas Pharma; Black Diamond Therapeutics; Bristol-Myers Squibb; Dompé Farmaceutici; Exact Sciences; Fulcrum Therapeutics; Ipsen; Merck Serono; Novartis; Pfizer; Takeda
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst)
 
Thomas Powles
Honoraria - Astellas Pharma; AstraZeneca; BMS GmbH & Co. KG; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson/Janssen; MashupMD; Merck; Merck Serono; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; MashupMD; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche